Systematic review and meta-analysis of the effectiveness of pharmacist-led medication reconciliation in the community after hospital discharge

Duncan McNab,1,2 Paul Bowie,1,2 Alastair Ross,3 Gordon MacWalter,1 Martin Ryan,1 Jill Morrison2

ABSTRACT
Background Pharmacists’ completion of medication reconciliation in the community after hospital discharge is intended to reduce harm due to prescribed or omitted medication and increase healthcare efficiency, but the effectiveness of this approach is not clear. We systematically review the literature to evaluate intervention effectiveness in terms of discrepancy identification and resolution, clinical relevance of resolved discrepancies and healthcare utilisation, including readmission rates, emergency department attendance and primary care workload.

Methods This is a systematic literature review and meta-analysis of extracted data. Medline, Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, Allied and Complementary Medicine Database (AMED), Education Resources Information Center (ERIC), Scopus, NIH Evidence and the Cochrane databases were searched using a combination of medical subject heading terms and free-text search terms. Controlled studies evaluating pharmacist-led medication reconciliation in the community after hospital discharge were included. Study quality was appraised using the Critical Appraisal Skills Programme. Evidence was assessed through meta-analysis of readmission rates. Discrepancy identification rates, emergency department attendance and primary care workload were assessed narratively.

Results Fourteen studies were included, comprising five randomised controlled trials, six cohort studies and three pre–post intervention studies. Twelve studies had a moderate or high risk of bias. Increased identification and resolution of discrepancies was demonstrated in the four studies where this was evaluated. Reduction in clinically relevant discrepancies was reported in two studies. Meta-analysis did not demonstrate a significant reduction in readmission rate. There was no consistent evidence of reduction in emergency department attendance or primary care workload.

Conclusions Pharmacists can identify and resolve discrepancies when completing medication reconciliation after hospital discharge, but patient outcome or care workload improvements were not consistently seen. Future research should examine the clinical relevance of discrepancies and potential benefits on reducing healthcare team workload.

BACKGROUND
There is growing policy interest in improving the safety of transition between different health service locations or settings.1–4 Transitions include admission to hospital from the community, transfers within secondary care and discharge back to the community. Safe transitions often require coordinating care with healthcare professionals in both primary and secondary care and providing patients with accessible information on post-transition care.5 One area where these actions are crucial is in communicating medication information. Harm from prescribed or omitted medications is higher after discharge, and effective medication reconciliation has been promoted as one way to improve safety.1–4 6–8 Multiple definitions of medication reconciliation exist, but all involve defining the list of medications the patient should be taking, altering records to reflect changes and ensuring patients and/or carers are aware of the changes.1,3–9

At the transition from hospital to community, medication reconciliation is necessary for hospital-initiated medication changes to be maintained. The medication taken by patients in the community, and prescribed by their general practitioner or primary care physician (from now on both termed GP), is often changed during hospitalisation.4 10 On discharge, a document is sent to the patient’s GP, and sometimes their community pharmacist, detailing medication regimen changes implemented during their inpatient stay. Medication reconciliation ensures the list held by the GP or community pharmacist (preadmission medication) is updated to reflect hospital-initiated changes.
Following this process, discrepancies that exist between the primary care list of medications and the discharge medication list are either intentional discrepancies (a conscious decision has been made not to implement changes) or unintentional.

From the perspective of the UK, models for providing primary healthcare are changing. As in many sectors of healthcare, the roles of pharmacists (and other health professionals) are being extended. Completion of medication reconciliation by community pharmacists (whose traditional role is medication dispensing) and primary care pharmacists (employed by primary care organisations) has been prioritised. It is assumed this will increase the safety of care after discharge, improve outcomes such as readmission rate and have workload benefits by freeing clinical time for GPs. While in secondary care improvements in patient outcomes of this type of intervention have been reported, effectiveness in the community has not been established. A previous systematic review that examined all interventions to improve medication reconciliation in primary care found two studies that evaluated medication reconciliation after hospital discharge by pharmacists. These were of low quality and evidence of benefit was not found. A further systematic review evaluated all interventions (including medication reconciliation) undertaken by pharmacists in the community after hospital discharge. This showed that pharmacists can identify potential drug-related problems, but the impact on outcomes, such as healthcare utilisation, was inconsistent.

We aimed to focus, in depth, on medication reconciliation performed by community and primary care pharmacists after hospital discharge, by systematically reviewing published studies that compared this process with usual care. The aim was to determine the effectiveness of this intervention on overall discrepancy identification and resolution, the clinical relevance of resolved discrepancies and healthcare utilisation in terms of readmission rates, emergency department attendance and primary care workload.

METHODS

The study was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) group guidelines. The completed PRISMA checklist is included as an online supplementary file.

Scope of the review

Studies were included that compared community and primary care-based pharmacist-led medication reconciliation with usual practice. We defined medication reconciliation as the reconciliation of preadmission and postadmission lists of medication. Many studies evaluated interventions that included medication reconciliation combined with other actions. Studies where drug-related problems (such as drug interactions) were identified and corrected were included, but studies focused on medication review (eg, recommendations to optimise medication regimens) were not. Randomised controlled trials (RCTs), cohort studies and pre–post intervention studies were included.

Information sources

We searched the Medline (Ovid), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCOhost), EMBASE (Ovid), Allied and Complementary Medicine Database (AMED) (Ovid), Education Resources Information Center (ERIC) (Ovid), NHS Evidence, Cochrane electronic databases and Scopus databases from inception until 1 September 2017. The reference lists of selected studies were hand-searched to identify any additional relevant studies. Citations were imported into RefWorks and all versions of citations lists were kept.

Search strategy

To identify studies pertaining to our definition of medication reconciliation, a combination of medical subject heading terms and free-text search terms was developed by the review team in collaboration with a knowledge manager, a qualified librarian whose role includes searching and accessing published healthcare evidence. To identify studies describing medication reconciliation, the search terms ‘medication reconciliation’, ‘medicines reconciliation’, ‘medication discrepancy’, ‘medication error’, ‘medication discrepancy’ and ‘medication counselling’ were combined. Search terms to identify studies at discharge from hospital included ‘discharge’, ‘transition’ and ‘patient transfer’, and terms to identify pharmacists included ‘pharmacist’, ‘pharmacy’ and ‘community pharmacy’. To identify studies set in the community rather than in hospital, several terms were combined, including ‘primary health care’, ‘ambulatory care’, ‘family practice’, ‘general practitioner’ and ‘home care services’. No limit was placed on date of publication or language, and the search was adapted for each database. The final search syntax for Medline is available as an online supplementary file.

Eligibility criteria

For inclusion, studies had to fulfil the criteria in table 1. Following removal of duplicates, two reviewers independently screened titles and abstracts of all citations (DM and MR). Full texts of all articles considered to be relevant were obtained and screened by two reviewers independently (DM and MR). Disagreements were resolved by discussion of full article content with the remaining reviewers.

Data extraction

Once the final set of studies was agreed, the lead reviewer (DM) extracted data from all studies. A second data extraction was completed independently by another member of the review team. A template
was created to allow collection of data relevant to the study questions. This was piloted with two studies and adapted following discussion of extracted data by the review team. The data extracted comprised details of the authors, publication, funding, aims, study design, inclusion and exclusion criteria, method of allocation to intervention or control group, sample sizes, participant characteristics, setting and details of the intervention, statistical techniques used, outcome data, and reported strengths, weaknesses and conclusions.

Study details were tabulated to codify the study design, type of pharmacists, setting of intervention, number, timing and duration of contacts, and the description of collaboration with other team members. The outcome data that were extracted from each paper were rates of identification and resolution of discrepancies; rates of resolution of clinically relevant discrepancies; and measures of healthcare utilisation (rates of readmission, emergency department attendance, GP attendance, and the number of primary and secondary care appointments needed, and economic outcomes).

### Risk of bias

The quality of each study and risk of bias were assessed independently by the two reviewers who performed the data extraction using the relevant Critical Appraisal Skills Programme (CASP) tools. These checklists facilitate a systematic approach to considering the presence or absence of certain elements within the study that may cause bias. Following completion of the CASP tool, the two reviewers discussed their findings for each study and graded the risk of bias as low, moderate or high. For example, one section asks: ‘Were controls recruited in an acceptable way?’ Selection bias may be introduced if participants are not randomised but could select allocation to the intervention or control group. Studies that recruited control groups in this manner would be deemed to have a higher risk of bias.

### Data synthesis and analysis

Studies were grouped into RCTs, case–control studies and pre–post intervention studies. Other than for readmission rate, meta-analysis of outcome data could not be performed due to lack of data, heterogeneity of data and method of reporting outcome. To synthesise discrepancy rate resolution and healthcare utilisation data, outcomes were compared narratively with the appraised risk of bias of each study defined by the weight given to findings.

Meta-analysis of readmission data was performed by calculating the Mantel-Haenszel risk ratio (RR) and 95% CIs. As interventions in the included studies varied, it was thought that there would not be one ‘true’ effect size; therefore, a random-effects model was used within the Cochrane Review Manager (RevMan) V.5.3 software to synthesise results by constructing a forest plot. For studies that reported outcomes over different durations, the longest follow-up period for which all data were presented was used for analysis. Statistical heterogeneity was assessed by calculating $I^2$, $\chi^2$, $F^2$ and P values. Publication bias was evaluated by construction and inspection of a funnel plot.

### RESULTS

The electronic database search identified 3220 citations, with four more identified from the reference lists of included studies. After removal of duplicates, 1610 citations remained. Following title and abstract review, 157 publications underwent full-text review. Fourteen studies met the inclusion criteria (figure 1).

### Characteristics of included studies

Five included studies were RCTs, six were cohort studies, two were pre–post intervention studies and one was a quality improvement (QI) project that presented a run chart detailing pre–post intervention data (table 2). Two studies were deemed to have a low risk of bias. Although they were not blinded, both studies were RCTs and described robust randomisation

### Systematic review

| Table 1 Study inclusion criteria |
|---------------------------------|
| **Characteristics**            | **Criteria for quantitative studies** |
| Population                     | Patients discharged from hospital to their permanent residence (home, residential unit or nursing home) |
| Intervention of interest       | Medicines reconciliation completed by a pharmacist based in the community |
| Comparator                     | Usual care processes for medication reconciliation |
| Outcome measure                | Discrepancy identification |
|                                 | Discrepancy categorisation |
|                                 | Healthcare usage (readmission, emergency department attendance, GP attendance) |
|                                 | Workload/efficiency measures—time to complete medicines reconciliation, effect on number of primary and secondary care appointments needed, and economic outcomes |
| Study design                    | RCTs, cluster RCTs, quasi-RCTs, cluster quasi-RCTs, controlled pre–post intervention studies, interrupted-time-series, cohort studies (prospective or retrospective), case–control studies, uncontrolled pre–post intervention studies |
| Language                       | No limitation |
| Publication date                | No limitation |

GP, general practitioner or primary care physician; RCTs, randomised controlled trials.
Techniques to intervention or control group that otherwise received similar care. All significant results were presented and treatment effects were presented in a precise manner. Eight studies were deemed to be of moderate risk of bias. RCTs in this group had less robust randomisation, had low numbers and were unable to account for all patients who entered the study (one reported a large dropout rate, and another had several patients who were unable to be reached by telephone for follow-up). Cohort studies in this group had robust methods to select controls and presented relevant data in a precise manner. Four studies had a high risk of bias. These studies had less robust methods for assigning patients to intervention or control groups, or did not present all information on group allocation.

Sample sizes ranged from 61 patients to 829. Interventions varied by the patient group targeted, the setting within which it was completed, and the timing and number of contacts. Most studies targeted those considered at higher risk of readmission either through age or presence of a long-term condition. Five studies evaluated medication reconciliation undertaken by the pharmacist in the patient’s home, whereas in three studies medication reconciliation was performed with the patient at a primary care clinic appointment. In one study, medication reconciliation was completed by telephone, and in another,
### Table 2: Description of study and intervention characteristics including collaboration between pharmacist and GP of included studies

| Study | Country | Study design | Risk of bias | Characteristics and number of participants | Setting | Contacts (n) | Timing of contacts | Length of follow-up observation | Collaboration with healthcare team |
|-------|---------|--------------|--------------|---------------------------------------------|---------|--------------|-------------------|---------------------------------|----------------------------------|
| Nazareth et al^22| UK | RCT | Low | DM, PB | Patients discharged from elderly care wards Intervention: 181 Control: 181 | Home visit by community pharmacist | 1 or 2 | 7–14 days | 3 and 6 months | Liaise with GPs |
| Holland et al^33| UK | RCT | Low | DM, JM | Age >80 on two or more medicines Intervention: 429 Control: 400 | Home visit | 2 | 14 and 60 days | 6 months | Send report to GP |
| Ho et al^29| USA | RCT | Moderate | DM, MR | Admitted to one of 4 Veteran Affairs hospital with acute coronary syndrome Exclude if used non-Veteran Affairs pharmacy Intervention: 122 Control: 119 | Primary care clinic | 2 | 7–10 days—visit 30 days phone call | 12 months | Send report to GP |
| Dogan et al^34| UK | RCT | Moderate | DM, GM | Age 16–79 recruited by ward pharmacist Intervention: 237 Control: 264 | Community pharmacy | 0 | N/A | N/A | Not clear |
| Hawes et al^25| USA | RCT | Moderate | DM, AR | Year 1: long-term condition or more than 3 admissions, or 8 or more medications Year 2: 8 or more medications Intervention: 24 Control: 37 | Primary care clinic | 1 | 3 days | 30 days | Seen prior to GP appointment |
| Shcherbakova and Tereso^26| USA | Cohort | Moderate | DM, JM | Patients enrolled in health plan 180 days before admission Intervention: 156 Control: 156 | Home visit | 1 | 8 days | 30 days | Contact GP to authorise changes |
| Kilcup et al^27| USA | Cohort | Moderate | DM, AR | Patients considered high risk for readmission Intervention: 243 Control: 251 | Home visit | 1 | 3–7 days | 30 days | Send report to GP |
| Setter et al^39| USA | Cohort | Moderate | DM, GM | Age >50 transitioning from acute to home care with long-term condition Intervention: 110 Control: 110 | Home visit | 1 | Not clear | 60 days | Work with community nurses and send report to GP |
| Tedesco et al^30| USA | Cohort | Moderate | DM, JM | Age >65 Intervention: 34 Control: 43 | Primary care clinic | 1 or 2 phone calls and follow-up face-to-face review if needed | Phone call within 3 days, face-to-face 7–14 days | 30 days | Discussed with GP |
| Polinski et al^31| USA | Cohort | High | DM, JM | Considered high or moderate risk of readmission Intervention: 131 Control: 131 | By telephone or in patient home | Mean number contacts 5; details not fully reported | 3 days | 30 days | Contacted GP to arrange appointments and report medication changes and health concerns |

Continued
Systematic review

Reconciliation was performed either at a home visit for those with high risk of medication-related problems or by telephone for those with moderate risk.31 Two were set in nursing homes29 34 and one in a community pharmacy.24 In two studies medication reconciliation was completed in the absence of the patient.24 32

In seven studies patients were contacted once,25–29 33 34 in two studies twice, 17 23 and in three studies the number of contacts varied dependent on patient preference and perceived need by pharmacists.22 30 31 Medication reconciliation was completed 2 days before hospital discharge to the nursing home in one study.34 Six studies contacted the patient within the first week of discharge 25 27 29–31 33  and four in the second week. 17 22 23 26 In seven studies pharmacists discussed outcomes of medication reconciliation with other team members such as the GP or nursing staff,22 27 28 whereas in four a written report was produced for other clinical staff.17 23

Effectiveness of identification, resolution and clinical relevance of discrepancies

The identification and resolution of discrepancies by pharmacists completing medication reconciliation was compared with usual care in four studies.24 25 28 32 In all four studies, rates of identification and resolution were greater in the intervention group (table 3).

Two studies compared the clinical relevance of resolved discrepancies between intervention and control groups and suggested that there was the potential for fewer adverse drug events after pharmacists completed medication reconciliation (table 3).24 29 Seven studies described the type of discrepancy found (such as drug–drug interaction identified) but did not describe the clinical relevance.25–28 31 32

Healthcare utilisation

Healthcare utilisation was reported in 12 of the included studies. The different outcome measures reported included readmission rate at 1, 3, 6 and 12 months, emergency department attendance, and additional GP and secondary care consultations (table 3).

One study reported a reduced readmission rate, 25 31 whereas one reported no change.22 Two studies reported readmission rates over different time scales.22 27 In one study the longer time scale was used. The shorter time frame was used in the second study as the composite reported rates over different time scales.22 27 In one study the longer time scale was used. The shorter time frame was used in the second study as the composite frame was used in the second study as the composite

Table 2 Continued

| Study | Country | Study design | Risk of bias | Authors extracting data and assessing bias | Characteristics and number of participants | Setting | Contacts (n) | Timing of contacts | Length of follow-up observation | Collaboration with healthcare team |
|-------|---------|--------------|--------------|-------------------------------------------|-------------------------------------------|---------|-------------|-------------------|-------------------------------|----------------------------------|
| Zeitouni et al 33 | USA | Cohort | High | DM, GM | Identified as high risk of readmission | Telephone | 1 | 2 days | 30 days | Arranged appointment with GP |
| Boockvar et al 29 | USA | Pre/post intervention | Moderate | DM, GM | Nursing home residents | Nursing home | 1 | 1 day | 60 days | Send report to GP who responds to each request |
| Gray et al 32 | UK | Pre/post intervention | High | DM, MR | Discharged from elderly care wards | GP practice | None | None | N/A | Email, send note or discuss with GP if needed |
| Vuong et al 34 | Canada | QI project—pre/post intervention | High | DM, JM | Nursing home residents | Nursing home | 1 | 2 days before nursing home admission | 90 days | Three-way telephone call—pharmacist, nurse and GP |

GP, general practitioner or primary care physician; N/A, not applicable; QI, quality improvement; RCT, randomised controlled trials.

Table 2 continued on 23 July 2018 by guest. Protected by copyright.
http://qualitysafety.bmj.com/ BMJ Qual Saf: first published as 10.1136/bmjqs-2017-007087 on 16 December 2017. Downloaded from
| Study design | Study            | Risk of bias | Discrepancy resolution | Clinical relevance of discrepancies | Healthcare utilisation |
|--------------|------------------|--------------|------------------------|-------------------------------------|------------------------|
| RCT          | Nazareth et al\(^{22}\) | Low          | Not evaluated           | Not evaluated                       | No statistically significant effect on readmission rate or GP attendance at 3 and 6 months: Hospital readmission at 3 months: Intervention=64/164 (39.0%) Control=69/176 (39.2%) Hospital readmission between 3 and 6 months: Intervention=38/136 (27.9%) Control=43/151 (28.4%) Mean pharmacist time per visit: Journey time 17 min, visit time 38 min, admin time 32 min (total 1 hour 27 min) |
|              | Holland et al\(^{17}\) | Low          | Not evaluated           | Not evaluated                       | Increased readmission rate at 6 months by 30%: Total number admission over 6 months: Intervention=234/429 (54.5%) Control=178/426 (41.8%) Increased need for GP home visit by 43%: Intervention=204 visits Control=125 visits Rate ratio 1.41, \(P=0.002\) |
|              | Ho et al\(^{23}\)  | Moderate     | Not evaluated           | Not evaluated                       | No statistically significant reduction in readmission rate for revascularisation or for myocardial infarction at 12 months: Intervention=22/122 (18.0%) Control=26/119 (21.8%) Mean pharmacist time 3 hours 51 min |
|              | Duggan et al\(^{24}\) | Moderate     | Remaining unintentional discrepancy rate (per drug prescribed): Control=700/1328 (52.7%) Intervention=454/1408 (32.2%) | Consensus panel judged to have possible adverse effects: Intervention=51/1408 (3.6%) Control=83/1328 (6.3%) Definite adverse effect: Intervention=25/1408 (1.6%) Control=41/1328 (3.1%) Absolute risk reduction 5.3% Number Needed to Treat=19 |
|              | Hawes et al\(^{25}\) | Moderate     | Increased discrepancy resolution rate per patient: Intervention=6/12 (50%) Control=2/21 (9.5%) | Type of discrepancy reported not clinical relevance |

Continued
| Study design | Study | Risk of bias | Discrepancy resolution | Clinical relevance of discrepancies | Healthcare utilisation |
|-------------|-------|--------------|------------------------|----------------------------------|------------------------|
| Cohort      |       |              |                        |                                  |                        |
|             | Shcherbakova et al\(^{26}\) | Moderate | Pharmacist identified 301 medication-related problems in 156 patients=mean 1.93 per patient No figures reported for control group | Type of discrepancy reported not clinical relevance | No statistically significant effect on readmission rate at 30 days Intervention=16/156 (10.3%) Control=6/89 (6.7%) No statistically significant difference in emergency department attendance at 30 days Intervention=34/156 (21.8%) Control=13/89 (14.6%) |
|             | Kilcup et al\(^{27}\) | Moderate | Pharmacist resolved discrepancies present in >80% of patients (exact figures not given). Data on control group not measured and reported | Type of discrepancy reported not clinical relevance | Reduction of readmission at 7 days and 14 days but not statistically significant at 30 days 30-day readmission rate: Intervention=28/243 (11.5%) Control=34/251 (13.5%) (P=0.29) |
|             | Setter et al\(^{28}\) | Moderate | Increased resolution rate: Intervention=154/220 (70%) Control=139/231 (60%) Discrepancies classified as patient or system factors and not by clinical relevance | Reduced number of days admitted to hospital per patient in intervention group Intervention=0.4±1.2 Control=1.1±4.2 Reduced planned physician visits: Intervention=2.9±1.5 Control=3.5±2.7 Reduced unplanned physician visit: Intervention=0.2±0.6 Control=0.4±1.0 |
|             | Tedesco et al\(^{30}\) | Moderate | Not evaluated | Not evaluated | Readmission 30 days Intervention=5/34 (14.7%) Control=1/24 (26.7%) P=0.27 |
|             | Polinski et al\(^{31}\) | High | Discrepancy rate not reported | State 88 of 131 (67%) of medication reconciliation an omission of a prehospital medication or an identified gap based on clinical guidelines was identified Drug–drug interactions present in 21 of 131 (16%) of cases—no comment on severity | Reduced 30-day readmission rate Intervention group=16/131 (12.2%) Control group=29/131 (22.1%) Risk ratio (95% CI)=0.5 (0.29 to 0.88) |
|             | Zeitouni et al\(^{32}\) | High | Not reported | Not reported | Reduction in readmission at 1 month: Intervention=27% Control=43% |
readmission rate over the longer time frame was not clear. The pooled RR across all included studies (total number of patients=2336) was 0.91 (95% CI 0.66 to 1.25), indicating no clear effect on readmission rate (figure 2). There was a high degree of statistical heterogeneity. As few studies were included, $I^2$ is the most suitable statistic for assessing the impact of heterogeneity. An $I^2$ value of 71% and $P=0.002$ were calculated, indicating high heterogeneity.

Emergency department attendance rate was measured in three studies. No difference was observed between intervention and control groups in two studies, whereas in one a large reduction was found and this was a small RCT with a moderate risk of bias. One study reported an increase in GP visits of 43% in the intervention group, while another reported no significant difference in GP attendance. Two studies reported that pharmacist completing medication reconciliation had the potential to free up clinical time for other healthcare team members. One reported that 2 hours of pharmacist time freed 3 hours of nursing time and 1 hour of physician time, whereas in one a large reduction was found and this was a small RCT with a moderate risk of bias. One study reported an increase in GP visits of 43% in the intervention group, while another reported no significant difference in GP attendance.

**Table 3** Continued

| Study design | Study | Risk of bias | Discrepancy resolution | Clinical relevance of discrepancies | Healthcare utilisation |
|--------------|-------|-------------|-------------------------|-------------------------------------|------------------------|
| Pre/post intervention studies | Boockvar et al | Moderate | Found 696 discrepancies following 259 discharges=2.69 per patient (not measured in preintervention phase) | Calculated a drug discrepancy risk index; where this was raised, two reviewers reviewed notes to determine if possible discrepancy related adverse drug event: Postintervention=143 (2.3%) Preintervention=106 (14.5%) | No figures reported but state no difference in readmission rate; Physician responded to discrepancies: Awareness of discrepancy=429/598 (71.7%) Intention to review=415/598 (69.9%) Intention to adjust regimen=305/598 (51.2%) Intention to increase monitoring=239/598 (40.2%) |
| Gray et al | High | Increased resolution rate | Intervention=33 plans implemented out of 41 (80.5%) Control=23 plans implemented out of 45 (51%) | Examples of discrepancy listed but not quantified | 90-day readmission and emergency department attendance rate—no difference preintervention and postintervention; remained at median of 13% for each cohort Freed up 3 hours of nursing time and 1 hour physician time Consulted with pharmacist for 2 hours |
| Vuong et al | High | No preintervention data presented | Mean discrepancy rate of 2 per medication reconciliation reported postintervention | No preintervention data presented | Mean number of clinical concerns per medication reconciliation postintervention=6 |

GP, general practitioner or primary care physician.

**Discussion**

The literature was systematically reviewed to evaluate the effectiveness of pharmacist-led medication reconciliation performed in the community after hospital discharge. Pharmacists were more effective at identifying and resolving discrepancies compared with the usual care process. Meta-analysis did not demonstrate a statistically significant reduction in readmission rates, and the effect on emergency department attendance and workload of other healthcare team members was rarely measured and no consistent evidence of related benefit was found.

Comparison with previous literature

Several systematic reviews also reported the ability of pharmacists to effectively identify and resolve discrepancies in community and hospital settings. The clinical relevance of reduced discrepancy resolution was questioned in studies set in the community as many discrepancies remained after interventions and the effect on patient outcomes was not consistent. Several of our included studies derived their taxonomies empirically, which did not aid evaluation of clinical relevance empirically, which did not aid evaluation of clinical relevance empirically, which did not aid evaluation of clinical relevance empirically, which did not aid evaluation of clinical relevance empirically.
may be the reason why more discrepancies are identified.

Unlike our study, a recent systematic review and meta-analysis of pharmacist-led medication reconciliation in hospital performed at care transitions demonstrated a reduction in healthcare use after discharge.7 One possible explanation is that Mekonnen et al included studies with multiple intervention components, including patient education, follow-up telephone call, home visit, medication review, enhanced communication with primary care and the use of strategies to enhance adherence. Interventions in our systematic review included some of these components but excluded those describing a medication review and, as medication reconciliation was performed in the community, infrequently involved interventions to improve primary/secondary care communication. This may reflect the problem of varying definitions of medication reconciliation. The WHO defines medication reconciliation as ‘The formal process in which healthcare professionals partner with patients to ensure accurate and complete medication information transfer at interfaces of care’.1 Such a definition may legitimately include all the aspects of interventions included by Mekonnen et al. The Joint Commission definition of ‘The process of comparing a patient’s medication orders to all of the medications that the patient has been taking’ is more precise and may not include such diverse activities.7 It may be that these additional components are important to influence health outcomes; however, recent systematic reviews of pharmacist-completed medication reviews in various settings have failed to show a benefit to patient outcomes.38 39

It is reported that roughly half of all discharge communications have been found to contain unintended medications.40 Performing an accurate medication reconciliation using such a list is unlikely to improve patient outcomes as unintended medications will continue to be prescribed.17 However, even when medication is reconciled before discharge and patients followed up by pharmacists to improve adherence, clinically important medication errors and harm due to medication are not reduced.40

Implication for future policy and research
The lack of effect on patient outcomes raises the question of what role the pharmacists should play postdischarge. Patients are at a high risk of harm due to medication following discharge, and the involvement of pharmacists seems a logical step to reduce the risk of harm.41 Despite this, there is a paucity of high-quality studies investigating pharmacist-led medication reconciliation postdischarge, and the few that do exist do not provide conclusive evidence of benefit. At present, pharmacist-completed medication reconciliation postdischarge cannot be promoted to reduce harm and improve health outcome. Future research must do more than evaluate process measures such as discrepancy rate detection, and focus on evaluating the clinical relevance of resolved discrepancies such as potential or actual adverse drug events. This may be more resource-intensive as clinical review of notes is required to make judgements on clinical relevance.24 29 40 In addition, the development of an agreed taxonomy of discrepancies would be beneficial to aid process evaluation of such interventions and understanding of discrepancy relevance and why they occur.9

The lack of improvement in patient outcomes may be less important to policymakers and front-line clinical teams if reduction in workload pressures improves performance in other areas of primary care such as face-to-face clinical care or administrative tasks such as laboratory test results handling. High levels of workload are perceived as a major safety concern in UK general practice, and one of the main policy drivers of pharmacist role development is to free clinical and administrative time for GPs.42 The effect of pharmacist-led medication reconciliation on these related systems has not been studied previously and further research is clearly needed.

If the pharmacist’s role in medication reconciliation postdischarge is to free clinical time, then implementation at scale will require significant financial and personnel resources.43 Future research should determine if these predicted efficiency savings exist and if other healthcare team members, such as pharmacy technicians or existing primary care staff, can
**Strengths and limitations**

The search strategy included several relevant databases, with no limitation placed on date of publication or language. Broader terms than medication reconciliation were included in the search to incorporate studies reporting medication reconciliation as part of wider interventions. For example, although Holland et al describe their intervention as a medication review, we deemed it to be similar enough to our classification of medication reconciliation to be included. Screening for inclusion, data abstraction and quality appraisal were independently completed by two reviewers to enhance study rigour.

The study has several limitations. Some studies that would have been valuable in answering our questions may have been excluded as their focus of intervention was not on medication reconciliation per se.45 One study evaluated a community liaison pharmacist intervention but was based in hospital and so was excluded.46 Healthcare settings vary and findings from different countries may not be comparable. For example, studies were set in North American primary care services that may not be present in other areas.28

The CASP tools used to assess bias and quality are designed for use in RCTs and cohort studies and were adapted to assess the quality of QI projects and pre-post intervention studies. This led to these studies being treated as having a higher risk of bias. Several of the included studies were described as pilot projects25 32 or QI projects,27 33 34 and require more robust evaluation of their findings to determine if they are replicated at scale or in different settings. Included studies were generally of low to moderate quality and susceptible to bias, which means the positive outcomes reported in this systematic review must be treated with caution.

The meta-analysis of data from studies reporting readmission rates was limited to studies that reported similar outcomes; however, this approach may still be open to challenge. A high level of heterogeneity was identified with possible reasons including different study designs, settings, intervention components, outcome definitions and follow-up periods. This means that it is difficult to draw definitive conclusions from the meta-analysis other than to say that there is currently no firm evidence that readmission rate is reduced. Meta-analysis of other outcome measures was not possible due to heterogeneity of reported outcomes. For example, discrepancy identification rates were reported as the number of discrepancies per drug prescribed24; the number of patients in a study who had a discrepancy25; full or partial implementation of the patient plan12; and the number of discrepancies resolved.28 Despite the inclusion of a wide range of study type, publication bias may still influence results as demonstrated by the asymmetry of the funnel plot (figure 3). Of note, the smallest study showed the largest positive effect.25 It may be that smaller projects with less robust methods that did not show a positive effect were not published.

**CONCLUSIONS**

This systematic review has shown that pharmacists can identify and resolve discrepancies while completing medication reconciliation after hospital discharge; however, the clinical relevance of these discrepancies has rarely been reported. The evidence does not support a reduction in readmission rates and there is not consistent evidence that other measures of healthcare utilisation, such as emergency department attendance and GP appointments, are reduced. Future research in this area should compare the clinical relevance of discrepancies identified and measure if this process reduces workload and thus frees clinical time in primary care.

**Acknowledgements** The authors would like to thank Dr Lynda Cochrane for her guidance on the statistics used in this paper and Allan Gillies, NHS Education for Scotland, for assistance in designing the search strategy.

**Contributors** DM and MR performed title, abstract and full-text screening. All authors discussed disagreements to reach consensus. DM extracted data from all included studies. A second data extraction was completed independently for each included study. This was divided evenly between PB, AR, GM and JM. All authors reviewed and contributed to writing the manuscript.

**Competing interests** None declared.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** Search syntax for all databases and all
versions of citation lists are available from DM.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
1 World Health Organization. Action on patient safety – high five, 2014. http://www.who.int/patientsafety/implementation/solutions/high5/H5_InterimReport.pdf?ua=1 (accessed 11 Oct 2017).
2 Institute for Healthcare Improvement. Medication reconciliation to prevent adverse drug events. http://www.ihhi.org/topics/admedicationreconciliation/Pages/default.aspx (accessed 11 Oct 2017).
3 The Joint Commission. Using medication reconciliation to prevent errors. 2006 http://www.jointcommission.org/assets/1/18/SEA_35.pdf (accessed 11 Oct 2017).
4 ihub. Scottish patient safety programme in primary care. http://www.scottishpatientsafetyprogramme.scot.nhs.uk/programmes/primary-care (accessed 11 Oct 2017).
5 Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med 2009;150:178–87.
6 National Institute for Health and Care Excellence. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. London. 2015 https://www.nice.org.uk/guidance/ng5 (accessed 11 Oct 2017).
7 Mekonnen AB, Mclachlan AJ, Brien JA. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open 2016;6:e010003.
8 Lehnborn EC, Stewart MJ, Manias E, et al. Impact of medication reconciliation and review on clinical outcomes. Ann Pharmacother 2014;48:1298–312.
9 Almanareh E, Moles R, Chen TF. The medication reconciliation process and classification of discrepancies: a systematic review. Br J Clin Pharmacol 2016;82:645–58.
10 Michaelen MH, McCague P, Bradley CE, et al. Medication reconciliation at discharge from hospital: a systematic review of the quantitative literature. Pharmacy 2015;3:53–71.
11 The Royal Pharmaceutical Society and Royal College of General Practitioners. Joint policy statement on general practice based pharmacists. 2015 https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/building-the-workforce-new-deal-gp.pdf (accessed 11 Oct 2017).
12 The Scottish government. Prescriptions for excellence: a vision and action plan for the right pharmaceutical care through integrated partnerships and innovation. 2013 http://www.gov.scot/resource/0043/00434053.pdf (accessed 11 Oct 2017).
13 The Royal Pharmaceutical Society and Royal College of General Practitioners’ Joint policy statement on general practice based pharmacists. https://www.rpharms.com/Portals/0/RPS%20Document%20Library/Open%20Access/Policy%20Statements/rcgps-rps-joint-statement-on-general-practice-based-pharmacists.pdf (accessed 11 Oct 2017).
14 Bayoumi I, Howard M, Holbrook AM, et al. Interventions to improve medication reconciliation in primary care. Ann Pharmacother 2009;43:1667–75.
15 Nazar H, Nazar Z, Portlock J, et al. A systematic review of the role of community pharmacies in improving the transition from secondary to primary care. Br J Clin Pharmacol 2015;80:936–48.
16 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
17 Holland R, Lenaghan E, Harvey I, et al. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ 2005;330:293.
18 Barker A, Barlis P, Berlowitz D, et al. Pharmacist directed home medication reviews in patients with chronic heart failure: a randomised clinical trial. Int J Cardiol 2012;159:139–43.
19 Refworks. www.refworks.com (accessed 11 Oct 2017).
20 Critical Appraisal Skills Programme (CASP). http://www.casp-uk.net/#casp-tools-checklists/c18f8 (accessed 11 Oct 2107).
21 Cochrane Community.RevMan 5. Review manager 5 (RevMan 5) is the software used for preparing and maintaining cochrane Reviews. http://community.cochrane.org/tools/review-production-tools/revman-5 (accessed 11 Oct 2017).
22 Nazareth I, Burton A, Shulman S, et al. A pharmacy discharge plan for hospitalized elderly patients--a randomized controlled trial. Age Ageing 2001;30:33–40.
23 Ho PM, Lambert-Kerrner A, Carey EE, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome discharge: a randomized clinical trial. JAMA Intern Med 2014;174:2706–7.
24 Duggan C, Feldman R, Hough J, et al. Reducing adverse prescribing discrepancies following hospital discharge. Int J Pharm Pract 1998;6:77–82.
25 Hawes EM, Maxwell WD, White SF, et al. Impact of an outpatient pharmacist intervention on medication discrepancies and health care resource utilization in posthospitalization care transitions. J Prim Care Community Health 2014;5:14–18.
26 Scherbakova N, Tereso G. Clinical pharmacist home visits and 30-day readmissions in medicare advantage beneficiaries. J Eval Clin Pract 2016;22:363–8.
27 Kilcup M, Schultz D, Carlson J, et al. Postdischarge pharmacist medication reconciliation: impact on readmission rates and financial savings. J Am Pharm Assoc 2013;53:78–84.
28 Setter SM, Corbett CF, Neumiller JJ, et al. Effectiveness of a pharmacist-nurse intervention on resolving medication discrepancies for patients transitioning from hospital to home health care. Am J Health Syst Pharm 2009;66:2027–31.
29 Boockvar KS, Carlson LaCorte H, Giambanco V, et al. Medication reconciliation for reducing drug-discrepancy adverse events. Am J Geriatr Pharmacother 2006;4:236–43.
30 Tedesco GW, McDonaha JL, Skomo ML, et al. A pharmacist’s impact on 30-day readmission rates when compared to the current standard of care within a patient-centered medical home: a pilot study. J Pharm Pract 2016;29:368–73.
31 Polinski JM, Moore JM, Kryychenko P, et al. An insurer’s care transition program emphasizes medication reconciliation, reduces readmissions and costs. Health Aff 2016;35:1222–9.
32 Gray S, Urwin M, Woolfrey S, et al. Copying hospital discharge summaries to practice pharmacists: does this help implement treatment plans? Qual Prim Care 2008;16:327–34.
Zeitoun I R, Saha A, Gettys KE, et al. Improving transition of care for patients with high risk for readmission. *J Gen Intern Med* 2014;29:5486–5487.

Vuong V, O’Donnell D, Navare H, et al. BOOMR: better coordinated cross-sectoral medication reconciliation for residential care. *Healthc Q* 2017;20:34–9.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–58.

Mueller SK, Sponsler KC, Kripalani S, et al. Hospital-based medication reconciliation practices: a systematic review. *Arch Intern Med* 2012;172:1057–69.

Kwan JL, Lo L, Sampson M, et al. Medication reconciliation during transitions of care as a patient safety strategy: a systematic review. *Ann Intern Med* 2013;158:397–403.

Christensen M, Lundh A. Medication review in hospitalised patients to reduce morbidity and mortality. *Cochrane Database Syst Rev* 2013;2:CD008986.

Huiskes VJ, Burger DM, van den Ende CH, et al. Effectiveness of medication review: a systematic review and meta-analysis of randomized controlled trials. *BMC Fam Pract* 2017;18:5.

Kripalani S, Roumie CL, Dalal AK, et al. Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trial. *Ann Intern Med* 2012;157:1–10.

Forster AJ, Clark HD, Menard A, et al. Effect of a nurse team coordinator on outcomes for hospitalized medicine patients. *Am J Med* 2005;118:1148–53.

Bell BG, Reeves D, Marsden K, et al. Safety climate in English general practices: workload pressures may compromise safety. *J Eval Clin Pract* 2016;22:71–6.

Hodson K, Smith M, Blenkinsopp A, et al. Evaluation of the discharge medicines review service in wales: content analysis of discharge medicines reviews. http://www.cpwales.org.uk/Contract-support-and-IT/Advanced-Services/Discharge-Medicines-Review/ (accessed 11 Oct 2017).

Bailey JE, Surbhi S, Bell PC, et al. Using pharmacy technicians in a novel role as community health workers to improve transitions of care. *J Am Pharm Assoc* 2016;56:73–81.

Croft M, Rowett D, Spurling L, et al. Does the addition of a pharmacist transition coordinator improve evidence-based medication management and health outcomes in older adults moving from the hospital to a long-term care facility? Results of a randomized, controlled trial. *Am J Geriatr Pharmacother* 2004;2:257–64.

Bolas H, Brookes K, Scott M, et al. Evaluation of a hospital-based community liaison pharmacy service in Northern Ireland. *Pharm World Sci* 2004;26:114–20.